Treatment with Nkarta’s lead candidate NKX019 in two ongoing, early-phase clinical trials may soon be available in outpatient settings — potentially expanding access for people with ANCA-associated vasculitis (AAV) and other autoimmune disorders — thanks to a new regulatory nod. The company announced it has reached an agreement…